Inhibition of mTORC1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma – Molecular Cancer Therapeutics

This study showed that an experimental drug called CC-115 could improve the effectiveness of standard chemotherapy to treat late-stage lung squamous cell carcinoma without worsening the side effects of chemo. This preclinical study is important because it can lead to improvements in treating lung cancer using new combinations of drugs in patients who have very few treatment options. Co-author Dr. Sharon Pine was funded by the American Lung Association Lung Cancer Discovery Award.